[go: up one dir, main page]

ATE421976T1 - Fab fragmentbibliotheken und verfahren für deren verwendung - Google Patents

Fab fragmentbibliotheken und verfahren für deren verwendung

Info

Publication number
ATE421976T1
ATE421976T1 AT99201558T AT99201558T ATE421976T1 AT E421976 T1 ATE421976 T1 AT E421976T1 AT 99201558 T AT99201558 T AT 99201558T AT 99201558 T AT99201558 T AT 99201558T AT E421976 T1 ATE421976 T1 AT E421976T1
Authority
AT
Austria
Prior art keywords
methods
fab fragment
fragment libraries
fab
libraries
Prior art date
Application number
AT99201558T
Other languages
English (en)
Inventor
Hendricus Renerus Jacobus Hoogenboom
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp filed Critical Dyax Corp
Application granted granted Critical
Publication of ATE421976T1 publication Critical patent/ATE421976T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT99201558T 1999-05-18 1999-05-18 Fab fragmentbibliotheken und verfahren für deren verwendung ATE421976T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99201558A EP1054018B1 (de) 1999-05-18 1999-05-18 Fab Fragmentbibliotheken und Verfahren für deren Verwendung

Publications (1)

Publication Number Publication Date
ATE421976T1 true ATE421976T1 (de) 2009-02-15

Family

ID=8240210

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99201558T ATE421976T1 (de) 1999-05-18 1999-05-18 Fab fragmentbibliotheken und verfahren für deren verwendung

Country Status (11)

Country Link
EP (2) EP1054018B1 (de)
JP (3) JP4741086B2 (de)
AT (1) ATE421976T1 (de)
AU (1) AU780145B2 (de)
CA (1) CA2372582C (de)
DE (1) DE69940364D1 (de)
DK (2) DK1054018T3 (de)
ES (2) ES2321568T3 (de)
HK (1) HK1134303A1 (de)
PT (2) PT2067788E (de)
WO (1) WO2000070023A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60237704D1 (de) 2001-10-16 2010-10-28 Government Of The Us Secretary Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co-rezeptorkomplexen selektiert werden
AU2003239356B2 (en) 2002-05-06 2009-06-25 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Identification of novel broadly cross-reactive HIV-1 neutralizing human monoclonal antibodies
US7803913B2 (en) 2002-05-06 2010-09-28 The United States Of America As Represented By The Department Of Health And Human Services Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
ES2368733T3 (es) 2002-07-18 2011-11-21 Merus B.V. Producción recombinante de mezclas de anticuerpos.
US20040072262A1 (en) * 2002-10-11 2004-04-15 Montero-Julian Felix A. Methods and systems for detecting MHC class I binding peptides
KR20060015468A (ko) 2003-03-07 2006-02-17 뉴 잉글랜드 메디컬 센터 호스피털스 인코퍼레이티드 ＩｇＡ1 침착 질환 치료
US7157562B1 (en) * 2003-04-14 2007-01-02 The United States Of America As Represented By The Secretary Of The Army Bioprocess for the production of recombinant anti-botulinum toxin antibody
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP1639009B1 (de) 2003-05-30 2013-02-27 Merus B.V. Fab-bibliothek zur herstellung von einer mischung von antikörpern
EP1704251A1 (de) * 2003-12-15 2006-09-27 Institut Pasteur Repertoirbestimmung einer b-lymphozytenpopulation
EP1761561B1 (de) 2004-01-20 2015-08-26 KaloBios Pharmaceuticals, Inc. Antikörper-spezifitätstransfer mit minimal essentiell bindenden determinanten
DK1737971T3 (da) 2004-01-20 2017-11-13 Merus Nv Blandinger af bindingsproteiner
PT1735348E (pt) 2004-03-19 2012-07-24 Imclone Llc Anticorpo anti-receptor do factor de crescimento humano
MY146381A (en) * 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
EP1707628B1 (de) * 2005-03-30 2009-11-11 Sekisui Chemical Co., Ltd. Verfahren zur Produktion von rekombinanten polyklonalen Immunglobulinen
US8131480B2 (en) 2006-10-02 2012-03-06 Sea Lane Biotechnologies Llc Construction of diverse synthetic peptide and polypeptide libraries
CN101126760B (zh) * 2007-01-17 2011-11-16 江苏省人民医院 全人源抗卵泡刺激素β单链抗体筛选方法及其用途
US9365637B2 (en) 2010-02-19 2016-06-14 Japan Science And Technology Agency Antiviral agent, abzyme, primer set, method for producing polynucleotide, and method for producing polypeptide
JP6038121B2 (ja) 2011-04-21 2016-12-07 ガーバン インスティテュート オブ メディカル リサーチ 修飾された可変ドメイン分子及びその製造及び使用の方法ｂ
EP2761006B1 (de) 2011-09-28 2016-12-14 Zera Intein Protein Solutions, S.L. Spaltinteine und verwendungen davon
PL2838917T3 (pl) 2012-04-20 2019-12-31 Merus N.V. Sposoby i środki do wytwarzania heterodimerycznych cząsteczek podobnych do Ig
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
EP2883883A1 (de) 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Therapeutische Ziele und Mittel zur Behandlung von ischämiebedingten Reperfusionsschäden
BR112017021308A2 (pt) 2015-04-06 2018-09-25 Subdomain, Llc polipeptídeos contendo domínio de ligação de forma e uso dos mesmos
JP6987076B2 (ja) * 2016-04-06 2021-12-22 ズムトール バイオロジクス、インコーポレイテッド クローニング及びタンパク質発現のためのベクター、その方法、並びにその用途
MA45491A (fr) 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
CA3028002A1 (en) 2016-06-27 2018-01-04 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
US20200033347A1 (en) 2017-04-18 2020-01-30 Universite Libre De Bruxelles Biomarkers And Targets For Proliferative Diseases
WO2019089982A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
WO2019099433A2 (en) 2017-11-14 2019-05-23 Arcellx, Inc. D-domain containing polypeptides and uses thereof
JP7390729B2 (ja) 2018-03-23 2023-12-04 ユニヴェルシテ リブル ドゥ ブリュッセル Ｗｎｔシグナル伝達アゴニスト分子
CA3106115A1 (en) 2018-07-08 2020-01-16 Specifica Inc. Antibody libraries with maximized antibody developability characteristics

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4518564A (en) 1983-10-03 1985-05-21 Jeneric Industries, Inc. Gallium and silver free, palladium based dental alloys for porcelain-fused-to-metal restorations
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4798885A (en) 1986-02-07 1989-01-17 Genentech, Inc. Compositions of hormonally active human and porcine inhibin containing an α chain and 62 chain
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
CA2057923A1 (en) * 1989-05-16 1990-11-17 William D. Huse Co-expression of heteromeric receptors
KR100233781B1 (ko) 1989-11-06 1999-12-01 스테펜 에이. 쉐어윈 동종 재조합을 이용하는 단백질 제조방법
US5126323A (en) 1989-11-16 1992-06-30 Genetics Institute, Inc. Homogeneous purified k-fgf and compositions containing the same
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
DE4005633A1 (de) 1990-02-22 1991-08-29 Schuetz Werke Gmbh Co Kg Palettenbehaelter
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU662148B2 (en) * 1991-04-10 1995-08-24 Scripps Research Institute, The Heterodimeric receptor libraries using phagemids
PT101031B (pt) 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
ATE210189T1 (de) * 1992-09-04 2001-12-15 Scripps Research Inst Phagemiden die einen oberflächenrezeptor und ein heterologes oberflächenprotein co-exprimieren
WO1994028418A1 (en) 1993-05-28 1994-12-08 Baylor College Of Medicine Method and apparatus for desorption and ionization of analytes
AU677866B2 (en) 1993-08-26 1997-05-08 Board Of Trustees Of The University Of Illinois, The Neural regeneration using human bone morphogenetic proteins
EP0733109B9 (de) 1993-12-07 2006-07-05 Genetics Institute, LLC Bmp-12, bmp-13 und diese enthaltende sehne-induzierende zusammensetzungen

Also Published As

Publication number Publication date
WO2000070023A9 (en) 2002-01-17
JP4741086B2 (ja) 2011-08-03
EP1054018A1 (de) 2000-11-22
EP2067788B1 (de) 2015-07-22
DK1054018T3 (da) 2009-05-18
PT2067788E (pt) 2015-10-29
EP2067788A2 (de) 2009-06-10
EP1054018B1 (de) 2009-01-28
AU780145B2 (en) 2005-03-03
WO2000070023A1 (en) 2000-11-23
JP5159841B2 (ja) 2013-03-13
CA2372582A1 (en) 2000-11-23
AU5142200A (en) 2000-12-05
ES2321568T3 (es) 2009-06-08
HK1134303A1 (en) 2010-04-23
ES2549440T3 (es) 2015-10-28
CA2372582C (en) 2013-08-13
DK2067788T3 (da) 2015-10-19
DE69940364D1 (de) 2009-03-19
PT1054018E (pt) 2009-02-16
EP2067788A3 (de) 2010-04-21
JP2002543830A (ja) 2002-12-24
JP2013078315A (ja) 2013-05-02
JP2010273689A (ja) 2010-12-09

Similar Documents

Publication Publication Date Title
ATE421976T1 (de) Fab fragmentbibliotheken und verfahren für deren verwendung
NO2006008I2 (no) Natalizumab, anti alfa-4 integrin humanized monoclonal antibody
DK0933082T3 (da) Fremgangsmåde til manipulation af celledifferentiering
NZ334226A (en) Humanized immunoglobulin reactive with alpha 4 beta 7 integrin
ATE509955T1 (de) Humanisierte kollagen-antikörper und damit verbundene verfahren
ES2173130T3 (es) Metodo de fijacion de material al peptido beta-amiloide.
WO2005026209A3 (en) Monoclonal antibodies against hmgb1
ATE283926T1 (de) Antikörper gegen die alpha-kette von humanem interleukin 5 rezeptor
CY1111966T1 (el) Αντισωματα που δεσμευονται με κυτταροσυνδετο ca 125/0722ρ και μεθοδοι χρησεις αυτων
TW200516083A (en) Methods for making dual specificity antibodies
ATE531812T1 (de) Humanisierung von nager-antikörpern
CY1108663T1 (el) Αναστολεις της ενεργοποιησης συμπληρωματος
DE69417417D1 (de) Monoklonale antikörper gegen den alpha-pdgf-rezeptor und deren verwendungen
IT1271461B (it) Anticorpo monoclonale bispecifico anti-cd3/anti-egfr,processo per la produzione e suo uso.
WO2003087340A3 (en) Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof
DK0868427T3 (da) Fremgangsmåder til at idenficere forbindelser, der binder til et mål
EP1411962A4 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
ATE312622T1 (de) Verwendung von anti-hbp antikörper zur inhibierung der freisetzung von bradykinin
ATE229037T1 (de) Monoklonaler antikörper gegen denthrombin- antithrombin iii-komplex und dessen verwendung in immunoassays
IL139571A0 (en) A humanized antibody that binds to verotoxin, methods for the production thereof and pharmaceutical compositions containing the same
FR2710068B1 (fr) Dérivés de nucléosides, procédés de fabrication de ces dérivés de nucléosides et anticorps polyclonaux et monoclonaux spécifiques de ces dérivés.
HUP0003029A2 (hu) Ankrod specifikus monoklonális antitestek, antitestfragmentumok, keverékeik és alkalmazásuk

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1054018

Country of ref document: EP